Results 61 to 70 of about 12,590 (214)

Multimodal Multiorgan‐on‐a‐Chip Platform for Probing Liver‐Tumor Interactions and Advancing Prodrug Screening

Advanced Science, EarlyView.
This work introduces a multimodal multi‐OoC platform that overcomes current limitations in liver‐tumor interaction studies and prodrug screening. By integrating dynamic microfluidic circuits, electrochemical sensing, and mass analysis, this platform enables non‐invasive, longitudinal monitoring of drug metabolism and hepatotoxicity, offering a ...
Dan Wang, Yisong Huang, Weijian Zhao, Tian Chen, Siyu Bai, Denghui Guo, Mengying Wang, Yaoyao Zhao, Liang Zhao, Guangsheng Guo, Xiayan Wang   +10 more
wiley   +1 more source

Chronic Drug-Induced Liver Injury: Updates and Future Challenges

Frontiers in Pharmacology, 2021
Chronic drug-induced liver injury (DILI), defined as DILI with persistent liver injury more than one year after the first onset by the latest European guidelines, is a notable challenge globally with big issues of defining causality and establishing ...
Qiaoling Wang, Qiaoling Wang, Ang Huang, Jia-Bo Wang, Jia-Bo Wang, Zhengsheng Zou, Zhengsheng Zou   +6 more
doaj   +1 more source

Hepatitis E Virus Detection in Liver Tissue from Patients with Suspected Drug-Induced Liver Injury [PDF]

, 2015
Hepatitis E virus (HEV) infection is increasingly recognized as a cause of acute hepatitis in the industrialized world. We aimed to determine the frequency of acute Hepatitis E virus (HEV) infection in cases of suspected drug-induced liver injury (DILI),
Achim Weber, Erik Springer, Marion Bawohl, Obinna Chijioke   +3 more
core   +2 more sources

Adverse events in bedaquiline‐ and pretomanid‐based regimens for drug‐resistant tuberculosis from trial, implementation and pharmacovigilance studies

British Journal of Clinical Pharmacology, EarlyView.
Abstract The availability of safety data, particularly concerning adverse events (AEs) associated with the new shorter regimen for drug‐resistant tuberculosis (TB) containing a bedaquiline–pretomanid‐based regimen, is still limited. This systematic review aims to provide a comprehensive and updated analysis of AEs related to this new regimen by ...
Nisa Maria, Annisa Lazuardi Larasati, Indri Yuliani Hamdani, Jin‐Gun Cho, Jan‐Willem C. Alffenaar   +4 more
wiley   +1 more source

Amoxicillin-Clavulanate-Induced Liver Injury [PDF]

, 2016
Background and Aims Amoxicillin–clavulanate (AC) is the most frequent cause of idiosyncratic drug-induced injury (DILI) in the US DILI Network (DILIN) registry.
Andrew S. deLemos, David E. Kleiner, Don C. Rockey, Herbert L. Bonkovsky, Huiman X. Barnhart, Jiezhun Gu, Marwan Ghabril, null null, Robert J. Fontana   +8 more
core   +1 more source

The Liver Toxicity Knowledge Base (LKTB) and drug-induced liver injury (DILI) classification for assessment of human liver injury [PDF]

Expert Review of Gastroenterology & Hepatology, 2017
Drug-induced liver injury (DILI) is challenging for drug development, clinical practice and regulation. The Liver Toxicity Knowledge Base (LTKB) provides essential data for DILI study. Areas covered: The LTKB provided various types of data that can be used to assess and predict DILI.
Shraddha, Thakkar, Minjun, Chen, Hong, Fang, Zhichao, Liu, Ruth, Roberts, Weida, Tong   +5 more
openaire   +2 more sources

Prediction of Acute Liver Injury Trajectory in Patients Following Acetaminophen Overdose: A Multibiomarker Machine Learning Proof‐of‐Concept Study

Clinical Pharmacology &Therapeutics, EarlyView.
Clinical translation of novel therapies can be hindered by heterogeneity‐driven sample size inflation in late‐stage trials. In acetaminophen‐induced liver injury (APAP DILI), many patients recover spontaneously, diluting investigational drug efficacy signals.
Chris Humphries, Alastair M. Kilpatrick, Kathleen M. Scullion, Rhona Aird, Lorraine Bruce, Maria Elena Candela, Tak Yung Man, Stuart J. Forbes, James W. Dear   +8 more
wiley   +1 more source

Widely Targeted Liver Metabolomics Reveals Potential Biomarkers in Mice with Drug-Induced Liver Injury

Metabolites
Background: Drug-induced liver injury (DILI), a major type of adverse drug reaction, has become one of the leading causes of acute liver injury and liver failure worldwide.
Jiangning Peng, Tingting Zhao, Xuehong Zhang, Hong Wang, Hui Li, Yan Liang   +5 more
doaj   +1 more source

The Diagnosis and Manifestations of Liver Injury Secondary to Off-Label Androgenic Anabolic Steroid Use

Case Reports in Gastroenterology, 2016
Drug-induced liver injury (DILI) presents as a broad spectrum of adverse drug reactions which can range from a mild elevation in liver enzymes to fulminant liver failure.
Elena Cabb, Shanna Baltar, David Wes Powers, Karthik Mohan, Antonio Martinez, Eric Pitts   +5 more
doaj   +1 more source

Epigallocatechin-3-gallate Mo nanoparticles (EGM NPs) efficiently treat liver injury by strongly reducing oxidative stress, inflammation and endoplasmic reticulum stress

Frontiers in Pharmacology, 2022
Drug-induced liver injury (DILI) is a serious clinical disease associated with reactive oxygen species (ROS) burst and subsequent inflammatory responses.
Yunrong Yang, Yunrong Yang, Min Liu, Min Liu, Tianjiao Zhao, Tianjiao Zhao, Qiaohui Chen, Qiaohui Chen, Yuqi Yang, Yuqi Yang, Shuya Wang, Shuya Wang, Jinping Zhang, Jinping Zhang, Guiming Deng, Kewei Sun, Yayun Nan, Ke Cao, Kelong Ai, Kelong Ai, Qiong Huang, Qiong Huang   +21 more
doaj   +1 more source